Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
Dateline City: KENILWORTH, N.J. & MIAMI Clinical Studies of EIDD-2801 for the Treatment of Patients…
Dateline City: KENILWORTH, N.J. & NEW YORK New Collaboration to Leverage Complementary Expertise and Capabilities…
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA…
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced…
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
.jpg)
Dateline City: KENILWORTH, N.J. U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental…
Dateline City: KENILWORTH, N.J. Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six…
Dateline City: KENILWORTH, N.J. & SEATTLE KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
Dateline City: KENILWORTH, N.J. Additional sBLAs Filed Across All Approved Adult Indications KENILWORTH, N.J.–(BUSINESS WIRE)–Merck…
Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients…
Dateline City: KENILWORTH, N.J. First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine…
Dateline City: KENILWORTH, N.J. Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused…
Dateline City: KENILWORTH, N.J. Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour…
Dateline City: KENILWORTH, N.J. The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival…
Dateline City: KENILWORTH, N.J. & MELBOURNE, Australia Preclinical Data on Candidate Anti Malaria Agents Published…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at…
Dateline City: KENILWORTH, N.J. In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved…
Dateline City: KENILWORTH, N.J. Filing Receives Priority Review KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. — Merck (NYSE: MRK), known as MSD outside the…
Dateline City: KENILWORTH, N.J. Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in…
Dateline City: KENILWORTH, N.J. Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada,…
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…